alexa The use of Healthy Volunteers to Evaluate Bioequivalence of Antineoplasic Drugs: Pilot Studies with Capecitabine | OMICS International | Abstract
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

The use of Healthy Volunteers to Evaluate Bioequivalence of Antineoplasic Drugs: Pilot Studies with Capecitabine

Gustavo Duarte Mendes1,2,3, Tainah Babadopulos1,2, Lu Shi Chen2, Jaime O. Ilha2, José Cássio de Almeida Magalhães1,3, Khalid Alkharfy4 and Gilberto De Nucci4,5*

1Department of Pharmacology, State University of Campinas, Campinas, Brazil

2Galeno Research Unit, Campinas, Brazil

3Faculty of Odontology, University Camilo Castelo Branco (UNICASTELO), São Paulo, Brazil

4College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.

5Department of Pharmacology, Institute of Biomedical Sciences, University of Sao Paulo, São Paulo, Brazil

*Corresponding Author:
Gilberto De Nucci
415 Jesuino Marcondes Machado Ave.
13092-320, Campinas - SP, Brazil
Tel: +55-193251-6923
Fax: +55-19-3252-1516
E-mail: [email protected]

Received Date: September 05, 2011; Accepted Date: September 30, 2011; Published Date: October 03, 2011

Citation: Mendes GD, Babadopulos T, Chen LS, Ilha JO, de Almeida Magalhães JC, et al. (2011) The use of Healthy Volunteers to Evaluate Bioequivalence of Anti-neoplasic Drugs: Pilot Studies with Capecitabine. J Bioequiv Availab S1: 005. doi: 10.4172/jbb.S1-005

Copyright: © 2011 Mendes GD, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Capecitabine is a prodrug, is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil, by thymidine phosphorylase, which is generally expressed at high levels in tumors. Clinical and pharmacokinetics studies for capecitabine are perfomed in patients with cancer. The objective of the study was to evaluate the safety of a bioequivalence study (150 mg tablet) using healthy male volunteers under fasting and non-fasting conditions. The study was conducted with an open, randomized, two-period crossover design in a 2-week washout interval without food. After the study without food was completed, a new protocol was submitted to the Ethics Committee to evaluate the study with food. The volunteers were selected for the study after having their health status previously assessed by a clinical evaluation and laboratory tests (biochemical and hematological parameters, and urinalysis). A single capecitabine tablet (150mg) was given in each interment. An extra laboratory analysis was performed one week after the first administration of the drug for the safety of the subjects. Plasma capecitabine concentrations were analyzed by liquid chromatography coupled to tandem mass spectrometry (HPLC/MS/MS) with positive ion electrospray ionization using multiple reactions monitoring (MRM). The pharmacokinetic parameters were 529.38 (±265.22) and 462.88 (±425.85) ng.mL -1 for C max , 262.31 (±75.34) and 300.49 (±91.51) -1 for AUC last , and 0.66 (range 0.5 – 1.25) hr and 1.0 (range 0.33 – 1.33) hr for T max , without and with food, respectively, for the reference formulation. The intra-subject CV were 42.6% and 76.3% for C max and 9.64% and 20.3% for AUC last without and with food, respectively. The drug was well tolerated by the volunteers, and they presented no adverse reactions. The biochemical and hematological parameters presented no clinically relevant alterations. Our results indicate that it is safe to perform capecitabine bioequivalence studies in healthy male volunteers.

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version